



### **Problem**





90% of blindness is preventable or curable


Retinal abnormalities are asymptomatic, leading to late/no identification until its too late/expensive to save vision loss


Low Doctor: Patient ratio, far lower OCT: Patient ratio

32,68,00,000 Suspects: 3,40,00,000 Patients:

1,35,000 Doctors: <2,000 Devices

Long lead time for breaking even is the single largest reason for low penetration of the OCT





1

Identifies 20 retinal abnormalities viz.,

ERM, Myopic
Degeneration, Drusen,
Hypertensive DR,
Peripapilary Atrophy,
Tortuous vessels,
Macular Dystrophy,
Chorioretinitis,
Papilledema, Nevus,
FTMH, CRVO, BRVO,
Myelination, Glaucoma,
Cataract, ME, ARMD, RP
and CSR

2 Classifies DR into grades (ICDR):

No DR
DR1 | DR2 | DR3 | DR4


Shows 16 abnormalities identified to classify the retinal image into a particular grade of DR viz.,

Microaneurisms, hard exudates, cotton wool spot, DME, venous looping, FPD, FPE, NVD, NVE, vitreous HM, preretinal HM, laser, HM, VB, IRMA and high HM.

# DRISTi report







4

mental ARTELLIS

Explainable A.I.

### **Products**






Harnessing power of Artificial Intelligence, Robotics, 3D printing and Digital technologies to solve real world problems in identifying patients with retinal abnormalities


World's most
economical and
portable OCT

World's most accurate
and comprehensive
Al generated OCT report




# Artelus LCHP OCT





# Artelus \_CHP OCT



# Stage







**Generating revenues** 

Repeat purchases

Referrals













































### **Business models**





### Direct sales

(Private & Public Hospitals and NGOs)

### Screening as a Solution (SaaS)

(Hospitals, Pharmaceutical companies)

### Leasing

(Hospitals, Pharmaceutical companies)

AB PM-JAY reimbursement

(Revenue sharing)

### INR 2.37 Crores

Revenues generated in the first six months of FY 2023-24

INR 12.38 Crores

Orders & commitments in hand

### **USPs** and Future





DRISTI A.I.
USPs

High Accuracy (Sensitivity & Specificity) | Multi-pathology | Offline functioning

LCHP OCT USPs

World's most economical (Price, maintenance charges as well as cost of parts) I Image quality as good as gold standard I Made-in-India I World's most portable I DRISTI A.I.

DRISTI OCT way forward

Ability to identify seven retinal conditions with a high sensitivity, as compared to the current four

LCHP OCT way forward

1. ArMAC

World's first remotely operable OCT; DoT 5G Hackathon, DCIS 2023 grant

World's most economical intraoperative OCT (iOCT)
 K-Tech ELEVATE 2023 grant

3. Supine OCT

### **Team**







Pradeep Walia
Founder, Director
MBA, Carnegie Mellon
University; Ex-E&Y with
over 20 years in the IT
field as an
entrepreneur



Girish Somvanshi
Co-founder, Director
20 years in
Pharmaceuticals,
Nutraceuticals and IT
PGDBM; Marketing
Cipla, Abbott, Alkem,
Torrent, Head Vitabiotics
(Indonesia)



Dr. Ramesh s Ve
Head, Medical
Ex-Professor at Manipal
University (MaHE)
An authority in Retinal
abnormalities with 72
publications



Sagarnil Das CTO Intel Edge AI Scholarship Winner, NASA, New York State Department of Health (OBAMACARE), Computer Science Corporation (F500), Udacity (F500), etc



Abhik Maity
Head, Deep Learning
IIT-PhD
Eight years experience
with Infrrd and PRM
Fincon
Seven published
papers with 80+ citations

## Recognition





### Recognitions for Artelus

- ☆ ISO 13485:2016
- ☆ 18 patents
- ⇒ Presented our solutions to delegates of 29 Nations, at the G20-DIA conference
- ☆ Ranked 13<sup>th</sup> in India's MSME25 Innovation Index
- One of six Top Al start-ups out of 1,038 firms

#### **LCHP OCT Awards**

- ☆ Winner of Karnataka Govt's ELEVATE grant, 2023
- ☆ Winner of Central Govt's DCIS grant, 2023
- ☆ Winner of Central Govt's DoT 5G Hackathon, 2023
- ☆ Winner of LVPEI Start-up challenge, 2023
- ☆ Being evaluated by Indian Armed Forces
- ☆ Used for Home OCT screening project

#### DRISTI A.I. evaluation

- Deployed after competitive evaluation by Dubai Health Authority (DHA) and for an ICMR (India) project
- ★ Being evaluated by the Uganda MoH, the UK NHS and the Oman MoH

### DRISTi A.I. Research presented at

Advanced Technologies & Treatments for Diabetes

#### ATTD 2023 | ATTD 2022

- American Academy of Ophthalmology
  AAO 2018 | AAO 2017 | AAO 2016
- ★ Emirates Diabetes and Endocrine Congress EDEC 2018
- ☆ Asia Pacific Academy of Ophthalmology APAO 2017

#### DRISTi A.I. awards

- ☆ UNSW Founders: Health 10, Australia
- → PMJAY Start-Up Grand Challenge
- ☆ Qualcomm grant
- ☆ NASSCOM (NATC) Award
- ☆ Healthcare Product Summit (HCPS)
- ☆ Qualcomm Design in India challenge
- ☆ Digital Innovation challenge
- ★ Technology Innovation Pioneers, Abu Dhabi
- ☆ Pitch@Palace, UK
- ★ The Start Tel Aviv (TLV)

#### Media

★ More than 60 media publications featuring Artelus

Forbes
Telegraph UK
Economic Times
CNA Singapore
The Times of India
The National
Arab Health







# Girish Somvanshi 9820 89 4321 gsomvanshi@artelus.com